Attached files
file | filename |
---|---|
EX-99.1 - DERMA SCIENCES, INC. | v209879_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 3, 2011
Derma
Sciences, Inc.
(Exact name of registrant as specified
in its charter)
Pennsylvania
|
1-31070
|
23-2328753
|
(State
or other jurisdiction
|
(Commission
|
(IRS
employer
|
of
incorporation)
|
File
Number)
|
identification
number)
|
214
Carnegie Center, Suite 300
Princeton,
NJ 08540
(609)
514-4744
(Address
including zip code and telephone
number,
of principal executive offices)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other Events
On
February 3, 2011 Derma Sciences, Inc. (the “Registrant”) announced the results
of its Phase 2 clinical trial of DSC127 in patients with diabetic foot
ulcers. A copy of the press release issued by the Registrant in
connection with this announcement is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
(d)
|
Exhibits:
|
||
99.1 – |
Press
release dated February 3, 2011 entitled “Derma Sciences Reports Positive
Top-Line Results From DSC127 Phase 2 Trial in Patients with Diabetic Foot
Ulcers”
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
DERMA
SCIENCES, INC.
|
|
By:
|
/s/ John
E. Yetter
|
John
E. Yetter, CPA
|
|
Vice
President and Chief Financial
Officer
|
Date: February
3, 2011
EXHIBIT
INDEX
Exhibit
Number
|
Description
|
|
99.1
|
Press
release dated February 3, 2011 entitled “Derma Sciences Reports Positive
Top-Line Results From DSC127 Phase 2 Trial in Patients with Diabetic Foot
Ulcers”
|